Editor, Scrip & Pink Sheet, covering pharmaceutical and business news and analysis; views expressed are purely my own.

Read Full Bio →


Eleanor has been Editor of Scrip Intelligence since 2014. She has worked on the title since 2000, reporting and analysing all aspects of the global pharma industry from M&A and partnering, financial and strategy news and trends through R&D to market access, policy and regulation. She has ...

Search Tweets

Twitter Feed

@ScripEleanor — 1,994 followers, 2,799 tweets

Oct 31, 2017

RT @amandamicklus: $SNY also had opt ex-US rights to $VYGR FA gene tx & US co-comm rights to Huntington's gene tx - I wonder if still…

Oct 17, 2017

RT @ScripIanS: EMA publishes #Brexit business continuity plan, covering prioritisation of activities, reallocation of resources etc  http://bit.ly/2ihg5Eh 

Oct 17, 2017

RT @ScripIanS: #Brexit uncertainty hits pharma recruitment: “We're starting to see people turn us down in the UK,” AZ’s Mene Pangalos tells SciTech Cttee

Oct 16, 2017

RT @ExelixisInc: Just announced: $EXEL reports positive top-line results in ph. 3 trial for advanced #livercancer. Learn more:  http://bit.ly/2iedbjL 

Show More